Award Ceremony
the best Business Plans
and Business Ideas for tomorrow
We are pleased to present the winner of **venture** 2018 Business Idea Competition.

Out of 109 Business Ideas submitted, the Jury and Advisory Board members chose Artiria Medical. We congratulate Marc Boers and his team on this great success!

1st place – Artiria Medical

Artiria developed a disruptive medical device to help neuroendovascular surgeons treat stroke-patients. The system allows the surgeon to navigate quickly and safely through the brain arteries thanks to a micro-robotic tool. This device drastically improves the outcome of stroke-related procedures.

2nd – 5th placed teams

2nd: Microcaps

Microcaps has developed a versatile method to fabricate Microcapsules with precise size control. This enables our customers to fully control the behavior of such capsules, which play an essential role in Pharmaceuticals, Cosmetics, Agrochemicals, and many more industries.

3rd: Rapid Graft

Wounds or skin defects can have severe physical and psychological impact on patients. Often, these wounds require a skin transplant. Rapid Graft develops a tool to take precise skin grafts quickly and much more easily than existing techniques.

4th: SwissProsthetics

SwissProsthetics provides an affordable, modular, and robust prosthetic hand solution for children and adults. Our products facilitate better social integration and improve the quality of life for those affected. The project benefits from the real-life experiences of a father and his daughter.

5th: EmbryoSpin

EmbryoSpin is the first high-tech hardware company that will offer magnetic resonance instrumentation at the scale of a human embryo. Our long-term goal is to market a device for assessing the health and viability of embryos fertilised in vitro.

For the organizers

Prof. Dr. M. Ziegler
President
McKinsey & Company

Dr. T. Knecht
Founder of **venture**
Chairman Knecht Holding

A. Kudelski
President
Innosuisse

Prof. Dr. M. Vetterli
President
EPFL

We are pleased to present the winner of **venture** 2018 Business Plan Competition.

Out of 83 Business Plans submitted, the Jury and Advisory Board members chose EBA-Med. We congratulate Adriano Garonna and his team on this great success!

1st place – EBA-Med

300’000 patients in Europe are treated every year for heart arrhythmias using manual surgeries, which are scary, complex and lengthy. EBA-Med’s non-invasive solution based on proton beams enables the same treatment in a single session, whilst saving hospitals 5 times the time and 3 times the costs.

2nd – 5th placed teams

2nd: nanoleq

nanoleq is a spin-off of ETH Zürich with strong expertise in robust stretchable electronics. We offer unbreakable cables for critical applications in medical devices, robotics and consumer electronics.

3rd: INVOLI

INVOLI enables the safe integration of drones into the air traffic, thus avoiding collisions with aircraft and permitting new exciting applications (drone delivery, drone taxi). Our system provides the currently missing low-altitude air traffic data to drones, and thus allows a safe and shared sky.

4th: AgroSustain

AgroSustain develops efficient organic treatments to extend the shelf life of fruits and vegetables infected with fungal pathogens. AgroSustain’s products promote the reduction of food waste and plastic consumption by extending food shelf life.

5th: Araris

Araris develops antibody-drug conjugates (ADCs) for targeted cancer therapy. Generating ADCs with current methods is complex and expensive, and they often have limited stability and suboptimal efficacy. Without engineering, we can turn any native antibody into an ADC with optimal properties.

For the organizers

Prof. Dr. L. Guzzella
President
ETH Zürich

Dr. M. Ziegler
Senior Partner
McKinsey & Company

Dr. T. Knecht
Founder of **venture**
Chairman Knecht Holding

A. Kudelski
President
Innosuisse

Prof. Dr. M. Vetterli
President
EPFL
>Preface

Dear >>venture>> community,

We are delighted to present the finalists of the 13th edition of >>venture>>. The TOP 5 Business Plan and Business Idea teams who present themselves on stage today have proven to be the most outstanding among the 192 projects that were accepted to enter the competition this year.

Tonight’s first award ceremony at EPFL marks a new milestone in the Switzerland-wide presence of >>venture>>. Going forward, the award ceremony will move between Zurich and Lausanne. Another first is the participation of André Kudelski, President of Innosuisse, Chairman and CEO of Kudelski Group, and new board member of the >>venture foundation>>. We look forward to his keynote address.

>>venture>> 2018 would not have been possible without the invaluable contributions of the Advisory Board and the nearly 200 coaches, jurors and experts, who provide pro bono support to the >>venture>> teams. Our thanks go to all our supporters and our congratulations to the fantastic startup teams you will meet tonight. We wish you an unforgettable evening at EPFL!

For the organisers

<table>
<thead>
<tr>
<th>Prof. Dr. L. Guzzella</th>
<th>Dr. M. Ziegler</th>
<th>Dr. T. Knecht</th>
<th>A. Kudelski</th>
<th>Prof. Dr. M. Vetterli</th>
</tr>
</thead>
<tbody>
<tr>
<td>President ETH Zürich</td>
<td>Senior Partner McKinsey &amp; Company</td>
<td>Founder of &gt;&gt;venture&gt;&gt; Chairman Knecht Holding</td>
<td>President Innosuisse</td>
<td>President EPFL</td>
</tr>
</tbody>
</table>

[Signatures]
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program</td>
<td>6</td>
</tr>
<tr>
<td>Keynote</td>
<td>7</td>
</tr>
<tr>
<td>Events</td>
<td>8</td>
</tr>
<tr>
<td>Key facts</td>
<td>10</td>
</tr>
<tr>
<td>Finalists</td>
<td>18</td>
</tr>
<tr>
<td>Top 5 Business Plans</td>
<td>20</td>
</tr>
<tr>
<td>Top 6–25 Business Plans</td>
<td>30</td>
</tr>
<tr>
<td>Top 5 Business Ideas</td>
<td>32</td>
</tr>
<tr>
<td>Top 6–25 Business Ideas</td>
<td>42</td>
</tr>
<tr>
<td>Advisory board</td>
<td>44</td>
</tr>
<tr>
<td>Interviews</td>
<td>46</td>
</tr>
<tr>
<td>Jurors &amp; coaches</td>
<td>48</td>
</tr>
</tbody>
</table>
Program

18:30 Welcome by moderator Olivier Dominik, Journalist and Anchor at RTS
18:35 Speech by Martin Vetterli, President of EPFL
18:45 Speech by Thomas Knecht, Chairman of Knecht Holding
18:55 Presentation of the Audience Award by Pascal Crittin, Director General of RTS
19:00 Announcement of the >>venture>> 2018 TOP 5 Business Ideas
19:20 Speech by Marco Ziegler, senior partner at McKinsey & Company
19:25 Keynote by André Kudelski, Chairman and CEO of Kudelski SA, President of the Board of Innosuisse
19:45 Announcement of the >>venture>> 2018 TOP 5 Business Plans
20:10 Closing remarks by Lino Guzzella, President of ETH Zürich
20:20 Apéro at Foyer Campus

Keynote speaker:
André Kudelski
Chairman and CEO of Kudelski SA, President of the Board of Innosuisse

After earning his degree in physical engineering at EPFL, André Kudelski started his career as a Research and Development engineer with Kudelski SA in 1984. After a short assignment in Silicon Valley, André Kudelski became Managing Director of Nagravision, the pay television division of the Kudelski Group that he founded. He succeeded his father as Chairman and CEO of Kudelski SA in 1991.

Under Mr. Kudelski’s leadership, the Kudelski Group has become a world leader in security and end-to-end solutions for digital media, Internet of Things, cybersecurity and public access. The commercial activities of the Kudelski Group are rapidly expanding in the US, with the creation of a second headquarters in Phoenix (AZ) in 2016, while the Group maintains a strong R&D base at its historical headquarters in Cheseaux-sur-Lausanne (VD).

André Kudelski is President of Innosuisse, the successor organization of the federal Commission for Technology and Innovation (CTI), which supports science-based innovation in Switzerland. In this position, he is a member of the board of the >>venture foundation>>.
Events throughout the year

**February**

Kickoff  
- Get inspired  
- Get to know the >>venture>> community

Intro to Intellectual Property  
- Learn from an IP expert from the Swiss Federal Institute of Intellectual Property

Speed Coaching  
- Meet 5-10 coaches for 10 minutes  
- Find your mentor  
- Get input and ideas

**March**

Patent Search Workshop IPI  
- Deep-dive into patent search  
- Perform your own patent search

**April**

Pitch Workshop  
- Practice your own pitch  
- Learn from others  
- Find out dos and don’ts

**May**

Business Plan Booster  
- Meet 3 coaches for 45 minutes each  
- Receive feedback on your Business Plan in a 1-day workshop

Startup Speed Dating  
- Pitch in front of candidates  
- Find additional team members  
- Form new teams

Expert Clinic  
- Ask questions to experts from different fields  
- Learn more during 1-on-1 meetings

Meet the Supporters  
- Get to know more support organisations

**June**

Investor Day & Award Ceremony  
- Pitch your plan in front of investors  
- Meet investors 1-on-1  
- Celebrate the >>venture>> winners
Key facts 2018

**Startup Competition**
- **109** Business Ideas registered
- **372** registered participants
- **192** teams with projects
- **170'000** CHF awarded
- **21** of which former business ideas

**Networking**
- **1400** people attended
- **360** investor meetings
- **23** events organised
- **24** startup support organisations involved

**Coaching**
- **94** expert jurors
- **102** expert coaches
- **589** juror feedbacks
- **267** coaching matches

**Total**
- **210** events
- **265** CHF awarded
- **109** business plans
Geographic location of projects
Accepted projects, total 192

- **Lake Geneva Region**: 62 projects
- **Espace Mittelland**: 15 projects
- **North-Western Switzerland**: 18 projects
- **Central Switzerland**: 6 projects
- **Eastern Switzerland**: 9 projects
- **Zurich**: 78 projects
- **Liechtenstein**: 2 projects
- **Abroad**: 2 projects
Diversity

Most recent participant affiliation to institutes of higher education

2017 (100% = 355)
- EPFL: 20.5%
- ETH Zürich: 15.9%
- Other Swiss universities: 7.7%
- Swiss universities of Applied Science: 29.3%
- None: 5.7%

2018 (100% = 372)
- EPFL: 21.5%
- ETH Zürich: 16.8%
- Other Swiss universities: 9.2%
- Swiss universities of Applied Science: 29.3%
- None: 6.9%

Projects by industry
(as selected by teams)

All submitted projects
(100% = 192)
- Consumer Goods & Services, other: 23%
- High Tech, Industry: 34%
- ICT: 18%
- Life Sciences: 15%

Business Ideas
(100% = 109)
- Consumer Goods & Services, other: 30%
- High Tech, Industry: 29%
- ICT: 15%
- Life Sciences: 26%

Business Plans
(100% = 83)
- Consumer Goods & Services, other: 25%
- High Tech, Industry: 32%
- ICT: 16%
- Life Sciences: 27%
Age distribution of participants
(100% = 372)

Gender of participants
(100% = 372)

Professional status of participants
(100% = 372)
The 25 Business Plan Finalists

Life Sciences
- Aesyra 30
- Araris 22
- CARU 30
- Clemedi 30
- DispenCell 30
- EBA-Med 24
- Equsave 31
- Swiss MotionTech 31
- SwissSource Instruments 31
- TWIICE 31

Consumer Goods & Services
- AgroSustain 20
- Alver Golden Chlorella 30
- Biowatch 30
- Fund2.0 31
- LuckaBox 31

High Tech, Industry
- AVATronics 30
- Fixposition 30
- INVOLI 26
- MPower 31
- Nanogence 30
- Nanoleq 28

ICT
- KITRO 31
- Myesquare.com 31
- Pexapark 31
- Sevensense 31

The 25 Business Idea Finalists

Life Sciences
- Abodent 42
- Ärtiria Medical 32
- Lipidon Analytics 43
- Mabsense 43
- MABsolute 42
- Microcaps 36
- numex 43
- ONtrack Diagnostics 43
- Popticlear 42
- Rapid Graft 38
- Sleepiz 42
- SpheroBiotics 43
- SwissProsthetics 40

Consumer Goods & Services
- Delygate 42
- ICO Silkroad 43
- immobird 43

High Tech, Industry
- DROP 43
- EmbryoSpin 34
- Hades.ai 43
- Nanolockin 42
- swision 43
- UNISERS 43
- UniSieve 43

ICT
- advAIsor 42
- Vana Businesses 43
- Virtual Rails 43
Using a novel screening approach, AgroSustain has identified a number of antifungal compounds from plant extracts. Their first product originating from these has been shown to significantly extend the shelf life of vegetables, fruits, berries and cut flowers infected with agronomically important fungal pathogens. No toxic side effects have been found, and application can be performed by spraying. The company already has a strong concept of a supply chain and distribution path.

**What we do**

AgroSustain develops efficient organic treatments to extend shelf life of fruits and vegetables infected with fungal pathogens. Products of AgroSustain promote the reduction of food waste and plastic consumption by extending food shelf life.

**Why AgroSustain?**

Using a novel screening approach, AgroSustain has identified a number of antifungal compounds from plant extracts. Their first product originating from these has been shown to significantly extend the shelf life of vegetables, fruits, berries and cut flowers infected with agronomically important fungal pathogens. No toxic side effects have been found, and application can be performed by spraying. The company already has a strong concept of a supply chain and distribution path.

**What we need**

We are opening a seed round of investment in the quantity of CHF 900k to perform the certification of AgroSustain's first product and extend the team.

---

**AgroSustain**

Olga Dubey  
Sylvain Dubey  
Jean-Pascal Aribot

<table>
<thead>
<tr>
<th><strong>Industry</strong></th>
<th>Food, Beverage &amp; Tobacco</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>City</strong></td>
<td>Epalinges</td>
</tr>
<tr>
<td><strong>Affiliation</strong></td>
<td>UNIL, Agroscope</td>
</tr>
<tr>
<td><strong>Contact</strong></td>
<td><a href="mailto:olga.dubey@agrosustain.ch">olga.dubey@agrosustain.ch</a></td>
</tr>
</tbody>
</table>

---

Ruedi Gygax, member of the Jury Committee
Araris has submitted a very interesting Business Plan of outstanding quality. The early stage life-science company is active in the field of antibody drug conjugates (ADC), addressing an unmet medical need for novel cancer therapeutics. The company has developed a convincing technology that overcomes the limitation of currently used antibody drug conjugates and clearly separates them from competitors. The company is run by a multidisciplinary management team supported by experienced biotech entrepreneurs.

What we do
Araris develops antibody-drug conjugates (ADCs) for targeted cancer therapy. Generating ADCs with current methods is complex and expensive and they often have limited stability and suboptimal efficacy. Without engineering, we can turn any native antibody into an ADC with optimal properties.

What we need
We are in active discussions with pharma companies which want to test our ADC technology. To further explore collaboration opportunities, to build a powerful team and to start developing own ADCs, we are looking for CHF 2.5M seed investment.

Why Araris?
Araris has submitted a very interesting Business Plan of outstanding quality. The early stage life-science company is active in the field of an antibody drug conjugates (ADC), addressing an unmet medical need for novel cancer therapeutics. The company has developed a convincing technology that overcomes the limitation of currently used antibody drug conjugates and clearly separates them from competitors. The company is run by a multidisciplinary management team supported by experienced biotech entrepreneurs.

Philipp Spycher
Claudia Murar
David Muggli

Industry  Pharmaceuticals, Biotechnology & Life Sciences
City  Villigen
Affiliation  PSI
Contact  philipp.spycher@psi.ch
EBA-Med ticks all the boxes and is as solid as a project in this phase can be. The developed technology is appealing and the full implementation is based on other proven building blocks, which gives this venture an attractive technology risk profile. EBA-Med replaces existing procedures in a well-defined market with established price points. The advantages their non-invasive treatment brings is disruptive and makes it plausible both to enter the market in direct competition with incumbents, and to scale the business rapidly. Investors will appreciate the proven team and find the business proposition compelling.

300'000 patients in Europe are treated every year for heart arrhythmias using manual surgeries, which are scary, complex and lengthy. EBA-Med’s non-invasive solution based on proton beams enables the same treatment in a single session, whilst saving hospitals 5 times the time and 3 times the costs.

We are seeking investors for our Seed Round to fund the development and animal testing of a full prototype of our heart motion imaging and beam controlling system for protontherapy centers.

Why EBA-Med?

EBA-Med ticks all the boxes and is as solid as a project in this phase can be. The developed technology is appealing and the full implementation is based on other proven building blocks, which gives this venture an attractive technology risk profile. EBA-Med replaces existing procedures in a well-defined market with established price points. The advantages their non-invasive treatment brings is disruptive and makes it plausible both to enter the market in direct competition with incumbents, and to scale the business rapidly. Investors will appreciate the proven team and find the business proposition compelling.

Adriano Garonna
Giovanni Leo
Adi Kouadio

Industry: Health Care Equipment & Services
City: Geneva
Affiliation: EPFL
Contact: adriano.garonna@eba-med.com

Ulf Claesson, member of the Jury Committee
INVOLI enables the safe integration of drones into the air traffic, thus avoiding collisions with aircraft and permitting new exciting applications (drone delivery, drone taxi). Our system provides the currently missing low-altitude air traffic data to drones, and thus allows a safe and shared sky.

What we do
INVOLI enables the safe integration of drones into the air traffic, thus avoiding collisions with aircraft and permitting new exciting applications (drone delivery, drone taxi). Our system provides the currently missing low-altitude air traffic data to drones, and thus allows a safe and shared sky.

What we need
We are looking for Round A of CHF 4M by the end of 2018, advisors for business development, policy and regulation, industry connections and pilot projects.

Why INVOLI?
The jury liked INVOLI’s Business Plan, according to which the four-person management team will attempt to enable a safer airspace management infrastructure, basically allowing drones into today’s aviation world. Through an online platform, which gathers data from a network of Micro Control Towers, virtually everybody shall be able to see the surrounding air traffic (including airplanes, helicopters, drones, parachutists etc.). These intelligent tools will allow low-risk flights for all, unparalleled flight awareness and automatic collision avoidance strategies in a sky fuller of airborne vehicles than today. This need is growing fast and will have to be addressed with sound systems.

Dr. Søren Bjønness, member of the Jury Committee
nanoleq is a spin-off of ETH Zürich with strong expertise in robust stretchable electronics. We offer unbreakable cables for critical applications in medical devices, robotics and consumer electronics. We are currently raising our seed round. We are especially looking for investors with ties to relevant industries.

Why nanoleq?

The jury liked the product proposed by nanoleq as it solves a problem in the growing markets of robotics, medtech and personal sensors/headphones. The product is tangible, simple to use but complex in its material technology, thus making it protectable. Their advisory board is well rooted in the industry and should keep them focussed on the business. We expect this venture to turn their prototype into a profitable business very quickly.

Vincent Martinez, Luca Hirt, Flurin Stauffer, Serge Weydert

Industry Technology Hardware & Equipment
City Zurich
Affiliation ETH Zürich
Contact stauffer@nanoleq.com

What we do

nanoleq

What we need

We are currently raising our seed round. We are especially looking for investors with ties to relevant industries.

Why nanoleq?

The jury liked the product proposed by nanoleq as it solves a problem in the growing markets of robotics, medtech and personal sensors/headphones. The product is tangible, simple to use but complex in its material technology, thus making it protectable. Their advisory board is well rooted in the industry and should keep them focussed on the business. We expect this venture to turn their prototype into a profitable business very quickly.

Michael Watts, member of the Jury Committee
**AVAtronics** Noise Cancellation Technology is a superior patented HW/SW solution for reducing audio noise in headphones, smart devices & communication systems.

**CARU** is a communication and information tool that creates smart living spaces and connects generations.

**Clemedi** is combining genetics with machine learning algorithms to give you the right antibiotic.

**Nanogence** is disrupting the $1T construction market with ecofriendly, tailored additives that cut the cost over 40% and carbon emission up to 50%.

**Fixposition** provides low cost, high accuracy navigation with superior reliability. It is the key to make autonomous vehicles available to the greater population.

**Equisave** is dedicated to solving an animal welfare problem and aims to establish an in vitro production system for PMSG, a hormone used for breeding livestock.

**fund2.0** digitizes the value chain of a fast-growing class of structured products called Actively Managed Certificates.

**KITRO** is the first fully automated food waste management solution.

**LuckaBox** is an all-in-one on-demand supply chain solution to provide retailers with what their customers increasingly demand: on-demand deliveries.

**MPower Ventures** offer affordable solar power to 1.3 billion potential customers living off-grid or with an unreliable electricity grid in emerging markets.

**myesquare.com** is an online platform identifying potential energy savings in its users’ buildings and bolstering energy efficiency retrofits.

**Pexapark** is developing a fintech platform to help renewable energy investors secure their asset revenues in subsidy-free energy markets.

**Sevensense** is the provider of advanced autonomous navigation systems for the next generation of professional service robots.

**Swiss MotionTech** has developed a technology that is able to 3D print orthopaedic silicone parts. They now offer products that can be anatomically tailored to anyone.

**SwissSource Instruments** is a device that allow customers from academia and industry to perform multiple analysis with minimal sample preparation in less than a second.

**TWICE** develops innovative wearable solutions for people with mobility disorders, which help paraplegic people to walk again and therapists to rehabilitate stroke patients.
Worldwide around 150 million people live with undiagnosed cerebral aneurysm which can lead to stroke. The best way to prevent aneurysms is by neuro-endovascular surgery. Artiria Medical has developed a novel guidewire for more cost-effective and efficient brain surgery. The jury was convinced by the simple and clever patent pending technology as well as by the team. Next to their technical skills the founders bring several years of industry experience in Medtech.

Why Artiria Medical?
Worldwide around 150 million people live with undiagnosed cerebral aneurysm which can lead to stroke. The best way to prevent aneurysms is by neuro-endovascular surgery. Artiria Medical has developed a novel guidewire for more cost-effective and efficient brain surgery. The jury was convinced by the simple and clever patent pending technology as well as by the team. Next to their technical skills the founders bring several years of industry experience in Medtech.

What we do
Artiria developed a disruptive medical device to help neuroendovascular surgeons to treat stroke-patients. The system allows the surgeon to navigate quickly and safely through the brain arteries thanks to a micro-robotic tool. This device drastically improves the outcome of stroke-related procedures.

What we need
We are looking for a first investment in order to rapidly bring our solution to the market. We are also interested to collaborate with any clinical specialist in the field of interventional radiology.

Artiria Medical
Marc Boers
Guillaume Petit-Pierre

Industry: Health Care Equipment & Services
City: Lausanne
Affiliation: EPFL
Contact: info@artiria-medical.com

Dr. Marjan Kraak, member of the Jury Committee
In vitro fertilization (IVF) is a treatment for infertility or genetic problems. However, only 33% of women get pregnant after the 1st cycle. Still today, suitable embryos are selected using morphological analysis tools, mainly. EmbryoSpin aims at improving the embryo selection process using magnetic resonance read-outs of metabolites that indicate embryo viability. The jury was impressed by the proposed Business Idea that has the potential to increase overall IVF success rate.

EmbryoSpin is the first high-tech hardware company that will offer magnetic resonance instrumentation at the scale of a human embryo. Our long term goal is to market a device for assessment of health and viability of embryos fertilised in vitro.

We are currently looking for seed funding in order to complete those initial steps that will make our company grow. In order to serve initial customers and expand the customer base we also need new members in the technical team.

**Why EmbryoSpin?**

In vitro fertilization (IVF) is a treatment for infertility or genetic problems. However, only 33% of women get pregnant after the 1st cycle. Still today, suitable embryos are selected using morphological analysis tools, mainly. EmbryoSpin aims at improving the embryo selection process using magnetic resonance read-outs of metabolites that indicate embryo viability. The jury was impressed by the proposed Business Idea that has the potential to increase overall IVF success rate.
Microcaps brings precision and control to microencapsulation. The founders developed a novel microfluidic membrane for the tailored production of microparticles. Microencapsulation is needed everywhere, from pharmaceuticals and cosmetics to nutraceuticals and agrochemicals. As such, it is no surprise that the combined microencapsulation and microparticle market revenue forecast for 2018 is set at $11.9 billion USD.

What we do
Microcaps has developed a versatile method to fabricate Microcapsules with precise size control. This enables our customers to fully control the behavior of such capsules which play an essential role in Pharmaceuticals, Cosmetics, Agrochemicals and many more industries.

What we need
We are looking for specific pioneering projects to bring our technology to the market.

Why Microcaps?
Microcaps brings precision and control to microencapsulation. The founders developed a novel microfluidic membrane for the tailored production of microparticles. Microencapsulation is needed everywhere, from pharmaceuticals and cosmetics to nutraceuticals and agrochemicals. As such, it is no surprise that the combined microencapsulation and microparticle market revenue forecast for 2018 is set at $11.9 billion USD.
Rapid Graft addresses two sides of significant and common clinical skin problems with a device that reduces graft procedure to one click and one minute. First, it supports tissue engineering research that could benefit 6 million people per year with injuries resulting from burns or large wounds. Second, it enables outpatient treatment for the 1% of the population affected by chronic skin wounds such as leg ulcers. Researchers and dermatologists waited 60 years for this dermatome!

**What we do**

Wounds or defects of the skin can have severe physical and psychological impact on patients. Often, these wounds require a skin transplant. Rapid Graft develops a tool to take precise skin grafts quickly and much more easily than existing techniques.

**What we need**

We are looking for connections to leading burn and wound centres in Europe, meetings with persons who suffered from severe wounds to learn from their experience and investors with medtech expertise interested to join a future seed round.

**Why Rapid Graft?**

Rapid Graft addresses two sides of significant and common clinical skin problems with a device that reduces graft procedure to one click and one minute. First, it supports tissue engineering research that could benefit 6 million people per year with injuries resulting from burns or large wounds. Second, it enables outpatient treatment for the 1% of the population affected by chronic skin wounds such as leg ulcers. Researchers and dermatologists waited 60 years for this dermatome!

**Claude Florin, member of the Jury Committee**
The story of SwissProsthetics starts with the need to find a solution for a family member with upper limb loss to develop different prostheses in order to enable a variety of leisure activities. The result is an affordable and robust prosthetic device platform, allowing to easily develop different models for different applications. Versatility, robustness and affordability together with a design process on demand will allow for new solutions for people with disabilities and opens up a new way to scale-up the market. This Business Idea goes straight to your heart. Congratulations to the team.

SwissProsthetics provides an affordable, modular and robust prosthetic hand solution for children and adults. Our products facilitate better social integration and improve the quality of life for affected people. The project profits from real life experiences from a father and his daughter.

We are looking for CHF 300k to reach Design Freeze. Furthermore, we are looking for leads to people with the relevant connections and expertise in sales in the prosthetics field.

Why SwissProsthetics?
The story of SwissProsthetics starts with the need to find a solution for a family member with upper limb loss to develop different prostheses in order to enable a variety of leisure activities. The result is an affordable and robust prosthetic device platform, allowing to easily develop different models for different applications. Versatility, robustness and affordability together with a design process on demand will allow for new solutions for people with disabilities and opens up a new way to scale-up the market. This Business Idea goes straight to your heart. Congratulations to the team.

Marco Ruedi, member of the Jury Committee
Top 6-10 Finalists
(in alphabetical order)

**MABSolute** is a biotech startup with a scalable technology identifying urgently needed antibody-based therapeutics that can get marketed with pharma companies.

**NanoLockin** is developing instruments for the detection and analysis of nanoparticles in all kinds of products.

**Popticlear** is a start-up dedicated to bringing the next-generation therapy for systemic lupus erythematosus to the patients in need.

**Sleepiz** couples novel sensors with intelligent algorithms to measure human vital signs without any physical contact, in order to analyse behaviour and medically screen for sleep disorders.

**UNISERS** is a water impurity monitoring sensor which will help the semiconductors industry improve the reliability of chips.

**hades.ai** is applying artificial intelligence to make sewer infrastructure management more sustainable.

**ICO Silkroad** enables Swiss startups to reach mass Chinese investors at low cost through blockchain technology and provides Chinese investors secure, real time investment opportunities.

**immobird** enables registered homeowners to freely compare and select real estate agents on our online platform.

**Lipidon Analytics** offers lipidomic technologies to facilitate lipid profiling, quantification of low concentration lipids as well as sphingolipid analyses.

**Mabsense** is a diagnostics device that measures therapeutic antibodies in patient serum as a simple and cheap method to guide therapy.

**numex** is revolutionizing the orthopedic treatment process by a soft-tissue based planning technology for implant surgeries.

**ONtrack Diagnostics** is a biotech company focusing on the development of non-invasive assays for the screening, diagnosis and monitoring of oncological diseases.

**SpheroBiotics** has devised a technology platform that re-invents antibiotic discovery from nature’s microbial communities.

**Swision**’s software enhances workflows of human-involving tasks through AR glasses, resulting in improved quality, productivity and lower error-rates.

**UNISERS** is a water impurity monitoring sensor which will help the semiconductors industry improve the reliability of chips.

**UniSieve** has developed a membrane technology allowing cost-and energy-efficient separation of gases in the energy, cleantech, oil & gas and chemical industries.

**Vana Businesses** is about enabling any successful company to grow online.

**Virtual Rails** is a revolutionary next generation drone control technique that allows for safe, easy and intuitive usage of drones alongside humans and in challenging environments.

Top 11-25 Finalists
(in alphabetical order)

**Abodent** is a unique all-inclusive dental subscription at CHF 39.90 per month that includes any upcoming treatments without any selection when subscribing.

**advAIsor** is an AI that understands emotional states in the entirety of corporate communications, allowing for group-wide emotional leadership and happiness maximization.

**Delygate** empowers women (and men) to delegate everyday tasks in the domestic field to trusted service providers to regain their time to focus on what matters to them.

**DROP** is a new generation of electrochemical devices to bring cheap, efficient and reliable water disinfection to low-income countries.
The Advisory Board

Allianz
Severin Moser
Bruno Chiomento
Anja König

ascom
Holger Cordes
Christian Buhl
Patrick Amstutz

avalon
Francisco Fernandez
Hilti
Christoph Loos

BCV
Pascal Kiener
Alban Fischer

BKW
Suzanne Thoma
Julian Bertschinger

BOSCH
Ute Lepple
Christianie Leister

BUHLER
Calvin Grieder
François Gabella

CLARIANT
Harlof Kottmann
Patrick Amstutz

CREDIT SUISSE
Didier Denat
Mauro Saladini

DATWYLER
Paul Hägl
Frank Lehmann

DIEPOST
Dieter Bambauer

The Jury Committee
Selecting the Top 5

Business Ideas
Carole Ackermann
DiamondsCell, Zug
Pascal Allot
IBM, Geneva
Martin Barthalet
Celeroton, St. Gallen
Brigitte Baumann
Go Beyond Early Stage Investing, Zurich
Peter E. Burckhardt
EVA, Basel
Dario Calaffi
Darcal Sagl, Ticino
Carlo Centonze
HeiQ Materials, Zurich
Thomas Dübendorfer
Swiss ICT Investor Club, Schwyz
Bettina Ernst
Preclin Biosystem, Zurich
Nicola Fantini
Spectas, Schwyz
Claude Florin
Venture Concept, Vaud
Dragan Grabulovski
Grabulovski Consulting Services, Zurich
Marjan Kraak
ETH, Zurich
Monika Krüesi
MKP Consulting, Zurich
Stefan Kyora
JNB, Lucerne
Mauro Lattuada
EPFL, Vaud
Jim Lewin
Blackbird Projects, Zurich
Marco Rüedi
Axalbion, Vaud

Business Plans
Kaspar Binz
MolecularPartners, Zurich
Søren Bjønness
Euronext, Zurich

Media partner:

Romain Boichat
Corpus Health, Vaud
Ulf Claesson
BLR & Partners, Clinerion, Zurich
Bart Clarysse
ETH, Zurich
Nicola Fantini
Spectas, Schwyz
Antonio Gambardella
Fongit, Geneva
Ruedi Gygax
Business Angel, Basel-Land
Matthias Hölling
Technopark, Zurich
Markus Hosang
BioMedPartners, Basel
Corinne John
Redbiotec, Zurich
Arnd Kaltofen-Ehmann
Vi Partners, Zurich
Walter Looser
Kistler, Zurich
Donat Matthews
Self-employed, Zurich
Marco Piatti
Piatti Consultant, Zurich
Yves Pitton
VTX Telecom SA, Vaud
Penny Schiffer
Swisscom, Zurich
Andreas Schienker
Tamedia, Zurich
Anil Sethi
Entrepreneur in Residence ETH, Zurich
Michael Sidler
Redalpine Venture Partners, Zurich
Jean-Philippe Tripet
Aravis group of funds, Zurich
Michael Wacker
Wacker Biotech Consulting, Zurich
Michael Watts
Alpine Venture Partners, Geneva
A juror’s perspective

Corinne John
Corinne John is co-founder and Executive Vice President of Redbiotec AG, a Swiss biotechnology company developing immunotherapies against Herpes and cancer. She holds a PhD in biochemistry from ETH Zürich and an Executive Diploma from HSG. Corinne John is a juror in the Business Plan track of >>venture>> 2018.

There are a high number of life sciences start-ups competing in >>venture>>. Leveraging your own entrepreneurial experiences in this field, how do you select the best?

Based on more than a decade of hands-on entrepreneurship in the field of biotech, I look at Business Plans of life science start-ups from three main angles: - the product, service or technology which should be an innovative, unique, ideally patentable and scalable solution for problems in existing and evolving markets; - the team – the key to success – whether I believe that they can make the business happen; - the overall plan and whether it makes sense and is plausible to me. Since most life science Business Plans are pretty specialized topics, I like to double check my findings either with own research or with second expert opinions in my network. All in all selecting the best Business Plan is a matter of taking time and carefully looking out for the high potential start-ups of the future.

Insights from a coach

Yves Pitton
Yves Pitton is CEO of VTX Telecom, a Swiss-wide private telecom operator providing services to residential and corporate customers, and Board Advisor of Doky Inc., a start-up based in Palo Alto, California, which provides cloud-based workspaces for improved productivity, communication and collaboration. Yves Pitton is coach and juror in the Business Plan track of >>venture>> 2018.

Silicon Valley is often regarded as the ultimate start-up environment. When coaching >>venture>> projects, which insights or lessons from Silicon Valley can you share with them?

There are a lot of myths about the Silicon Valley. After several years living there, I believe the truth is rather simple: If you truly believe in yourself, if you are willing to take some risks, if you are not afraid of swimming against the stream, if you put around yourself people who share the same dream and together have some “muscles”, you can achieve unreasonable things! Have a dream, be inspirational and you will create followership. It’s not about the Silicon Valley: Switzerland has an amazing potential and is strongly positioned to create impact!
venture’s backbone: Our jurors, coaches and experts

Luc Gérardin
Dragan Grabulovski
Ronan Guirey
Ruedi Gygax
Aino Hacklin
Josef Haid
Paul Hälg
Alex Hardtmuth
Philipp Hasler
Jann J. Hatz
Aoife Hegarty
Peter Hilpert
Markus Hofer
Heinz Hohl
Matthias Hölling
Markus Hosang
Krissy Jackson
Michael Jahn
Corinne John
Adrian Kalt
Arnd Kaltofen-Ehmann
Olivier Keiser
Pascal Kiener
Katharina Kirchhoff
Lutz Kirschner
Jürg Knecht
Stephan Knecht
Stephan Otto Knecht
Sybille Korrodi
Marjan Kraodi
Tom Krug
Monika Krüsi
Francis Kuhlen
Peter Kuhn
Stefan Kyora
Matt Lanfear
Mauro Lattuada
Frank Lehmann
Ute Lepple
Jim Lewis
René F. Lisi
Rana Lonnen
Christoph Loos
Walter Looser
Massimo Lucchina
Davide Manetti
Reto Margadant
Jerome Mariethoz
Marzio Massignani
Rudolf Matter
Donat Matthews
Manuel Meyer
Silke Meyns
Igor Milat
Joyce Miller
Elisabeth Moning
Philippe Monnier
Richard Munton
Simon Nebel
Georg Oberdick
Pedro Paiva
Vincenzo Pallotta
Silvia Panigone
Andrey Petrichtche

Many thanks

Carole Ackermann
Lavinia Alberi
Pascal Allot
Helder Amaral
Abdelaziz Amraoui
Reinhard Anton
Bernard Attas
Hugo Bague
Martin Bartholet
Michal Bartos
Brigitte Baumann
Peter Baumgartner
René Becker
Mark Belsey
Julian Bertschinger
Kasper Binz
Søren Bijnness
Stefan Blarer
Rico Blaser
Salvatore Bocchetti
Romain Boichat
Lamine Brahimi
Hanna Brahme
Daniel Brandenburger
Aron Braun
Christian Buhl
Fabian Buller
Peter Burckhardt
Peter E. Burckhardt
Christian Bürki
Martin Buyle
Dario Caleffi
Adriel Caro
Indro Celia
Carlo Centonze
Rico Chandra
Ulf Claesson
Bart Clarysse
Olivier Crochat
Charles d’Heureuse
Philippine Dalla Corte
Eli De Friend
Isabelle de Melo
Markus Decker
Didier Denat
Bruno Derungs
Thomas Dübendorfer
Rolf Eleveld
Andreas Emmendoerffer
Anna Engströmer
Alex Enzler
Bettina Ernst
Nicola Fantini
Nathalie Feingold
Josef Felber
Aldo Ferrari
Alban Fischer
Peter E. Fischer
Claude Florin
Herve Flutto
Jan Fülscher
Patrick Galliker
Antonio Gambardella
Marcos Garcia Pedraza

- Many thanks
- Our jurors, coaches and experts
- venture’s backbone
venture’s backbone: Our jurors, coaches and experts

Marco Piatti
Niccolo Pini
Yves Pitton
Evgeny Plaksen
Peter A. Plötz
Andreas Plüss
Sylvia Polydor
Lukas Reinhardt
Matthias Reinhart
Frank Reitgassl
Liliane Ritzi
Norman Rohr
Johan Roman
Dennis Rubner
Christoph Ruchti
Marco Rüedi
Mauro Saladini
Isabelle Saler
Frédéric Sauzet
Josef Schabauer
Julia Schieber
Ralph Schiess
Penny Schiffer
Philippe Schlegel
Andreas Schlenker
Martin Schneider
Shila Schneider
Franz Schubiger
Gabriele Schwarz
Philipp Schwarz
Andy Schwarzenbach

Alex Seidel
Anil Sethi
Michael Sidler
Katrin Siebenbürger Hacki
Emir Sirage
Bernard Spycher
Frido Stutz
Pietro Supino
Christian Suter
Tomas Svoboda
Albert Szabo
Evelyn Thar
Ramon Tissafi
Jean-Philippe Tripet
Fredrik Ullman
Graham Valentine
Heiko Visarius
Christian Vögeli
Peter J. Vonesch
Michael Wacker
Michael Watts
Kurt Weingarten
Mark West
Jeannette Wibmer
Matthias Wolf
David Yu
Richard Zbinden
Claudia Zimmermann

Contact

venture office
Phone: +41 (0)58 332 23 30
office@venture.ch
www.venture.ch

Imprint

venture 2018 is an initiative of the venture foundation, governed by ETH Zürich, McKinsey & Company Switzerland, Knecht Holding, Innosuisse and EPFL

Team photos and project descriptions were provided by the participating teams.

Editing: Lea Firmin, Lukas Kauz, Sander de la Rambelje, Aurélien Soccard

Reproduction of the contents of this booklet is authorized, provided the source is acknowledged.

Zurich, June 2018